SEC Form 4 · accession 0000899243-18-016632
MELINTA THERAPEUTICS, INC. /NEW/ · MLNT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sue Cammarata
Officer — Chief Medical Officer
Period of report
Jun 12, 2018
Accepted (ET)
Jun 14, 2018 · 4:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001461993
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $7.45 | Jun 12, 2018 | A | 80,000 | A | — | Apr 20, 2028 | Common Stock | 80,000 | 80,000 | D |
Explanation of responses
- F1The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018.
- F2One-quarter of the options will vest and become exercisable on April 20, 2019 and the remainder will vest and become exercisable in substantially equal monthly installments during the three year period commencing on April 20, 2019.